Influenza immune globulin - Emergent BioSolutions

Drug Profile

Influenza immune globulin - Emergent BioSolutions

Alternative Names: FLU IGIV; Intravenous hyperimmune immunoglobulin; NP 025

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emergent BioSolutions
  • Developer National Institute of Allergy and Infectious Diseases; University of Minnesota
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza A virus infections; Influenza B virus infections

Most Recent Events

  • 30 Oct 2017 Emergent Biosciences plans a phase II trial for Influenza-A virus infection (IV) in November 2017 (NCT03315104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top